Reducing depression during the menopausal transition: Study protocol for a randomised controlled trial by Almeida, Osvaldo P et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
1-1-2014 
Reducing depression during the menopausal transition: Study 
protocol for a randomised controlled trial 
Osvaldo P. Almeida 
Kylie Marsh 
Leon Flicker 
Martha Hickey 
Andrew Ford 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Health Psychology Commons 
10.1186/1745-6215-15-312 
Almeida, O. P., Marsh, K., Flicker, L., Hickey, M., Ford, A., & Sim, M. (2014). Reducing depression during the 
menopausal transition: study protocol for a randomised controlled trial. Trials, 15(1), 312. doi:10.1186/
1745-6215-15-312. Available here 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/210 
Authors 
Osvaldo P. Almeida, Kylie Marsh, Leon Flicker, Martha Hickey, Andrew Ford, and Moira Sim 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/210 
STUDY PROTOCOL Open Access
Reducing depression during the menopausal
transition: study protocol for a randomised
controlled trial
Osvaldo P Almeida1,2,3*, Kylie Marsh1,2, Leon Flicker1,4,5, Martha Hickey6, Andrew Ford1,2,3 and Moira Sim7
Abstract
Background: The menopausal transition (MT) is a biological inevitability for all ageing women that can be
associated with changes in mood, including depressive symptoms. There is tentative evidence that women who
develop depression during the MT have greater risk of subsequent depressive episodes, as well as increased health
morbidity and mortality. Thus, preventing depression during the MT could enhance both current and the future
health and well-being of women. This study aims to test the efficacy of a client-centred health promotion
intervention to decrease the 12-month incidence of clinically significant symptoms of depression among women
undergoing the MT.
Methods/Design: This randomised controlled trial will recruit 300 women undergoing the MT living in the Perth
metropolitan area. They will be free of clinically significant symptoms of depression and of psychotic or bipolar
disorders. Consenting participants will be stratified for the presence of subsyndromal symptoms of depression and
then randomly assigned to the intervention or control group. The intervention will consist of eight telephone
health promotion sessions that will provide training in problem solving and education about the MT, healthy
ageing, depression and anxiety, and management of chronic health symptoms and problems. The primary
outcome of interest is the onset of a major depressive episode according the DSM-IV-TR criteria during the
12-month follow-up or of clinically significant symptoms of depression, as established by a score of 15 or greater
on the Patient Health Questionnaire (PHQ-9). Secondary outcomes of interest include changes in the severity of
symptoms of depression and anxiety (Hospital Anxiety and Depression Scale, HADS), quality of life (Short Form
Health Survey, SF-12), and lifestyle.
Discussion: Current evidence shows that depressive symptoms and disorders are leading causes of disability
worldwide, and that they are relatively common during the MT. This study will use a multifaceted health promotion
intervention with the aim of preventing depression in these women. If successful, the results of this trial will have
implications for the management of women undergoing the MT.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12613000724774. Date registered:
1 July 2013.
Keywords: perimenopause, menopausal transition, depression, stress, anxiety, health promotion, prevention,
randomised controlled trial
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Background
Depression is a leading cause of disability and health-
related costs in Australia and worldwide [1,2], and af-
fects between 4 and 14% of the population at any point
in time [2]. The prevalence of depression is consistently
higher in women than in men across the reproductive
lifespan, with an increase in the prevalence of clinically
significant depressive symptoms noted during the years
that overlap with the menopausal transition (MT) [3-6].
The prospective midlife Study of Women’s Health Across
the Nation (SWAN) in the United States indicated that
nearly one in every four women experience clinically sig-
nificant depressive symptoms at this time [7]. This, to-
gether with further confirmatory studies, led the National
Institute of Aging to propose in 2010 that active screening
of depressive symptoms should become an integral part of
the assessment of all women going through the MT [8].
What is the menopausal transition?
All ageing women with intact ovaries go through the
MT, which is triggered by low ovarian follicular reserve
that leads to elevated follicle-stimulation hormone, fluc-
tuating oestradiol and reduced progesterone levels [9].
The MT commences at around age 47 and lasts 4 to
7 years [10]. The ‘menopause’ is the final menstrual per-
iod and occurs at a mean age of 51 years, and by age 55
nearly all women are postmenopausal [11]. Symptoms
typically associated with the MT include irregular men-
strual cycles, vasomotor symptoms (hot flushes and night
sweats), sleep disturbances, vaginal dryness and dyspar-
eunia, decreased libido, urinary symptoms, muscle and
joint pains, and mood disturbance [10]. Importantly, typ-
ical symptoms associated with the MT (for example, hot
flushes and night sweats) are amenable to change by
means of biological or behavioural interventions [12,13].
Why is the prevalence of depressive symptoms high
during the menopausal transition?
The reasons for the increased vulnerability to depres-
sion during the MT are not fully understood. Women
with past history of depression are nearly five times
more likely to have a recurrence of depressive illness
during the menopausal transition, whereas women with
no history of depression are two to four times more
likely to report depressed mood compared with preme-
nopausal women [6,14,15]. In some studies, the chan-
ging hormonal milieu has been associated with depressive
symptoms during the MT [16,17], but other factors
may be as important, such as prolonged hot flushes,
weight gain, comorbid diseases, poor social support,
changing psychosocial roles, anxiety and perceived loss of
control [18-21].
Can we prevent depression during the menopausal
transition?
Despite growing recognition that the MT is a period of
high vulnerability to depression, no previous studies
have attempted to prevent this happening. The spectrum
of physiological, psychological and social changes that
women undergoing the MT have to negotiate indicate
that effective preventive strategies must be multifaceted
(in the same way that strategies to reduce the prevalence
of cardiovascular events have greater chance of success
when multiple risk factors are targeted simultaneously,
such as hypertension, diabetes, dyslipidaemia, physical
activity, diet, alcohol use and smoking). Moreover, past
history of depression increases the risk of postmenopau-
sal depression, cardiovascular events, substance abuse
and mortality [22,23], the successful prevention and
treatment of depression during the MT is expected to
have long-term beneficial consequences for our ageing
population. Clinical recommendations on managing the
MT promote a broad approach to prevention and man-
agement of depression [24], including education, lifestyle
changes (diet, exercise, smoking, and alcohol consump-
tion), optimisation of general health and social support,
minimisation of vasomotor symptoms, problem solving
strategies and, if depression is prominent (that is, major
depressive episode or dysthymia), antidepressant treat-
ment and/or psychotherapy [25]. Oestrogen-containing
hormone therapy is recommended for women with mo-
derate to severe vasomotor symptoms without other
contra-indications [13], and preliminary evidence sug-
gests that it may also improve mood [16]. As the origin of
depression during the MT is most likely multifactorial, its
optimal management and prevention should target mul-
tiple factors, which is consistent with the results of suc-
cessful interventions designed to decrease the prevalence
of depression and suicide ideation in later life [26].
Women undergoing the menopausal transition require a
targeted health promotion intervention
The MT affects all ageing women with intact ovaries.
Marked physiological and psychosocial changes charac-
terise this unique period of a woman’s life, including
symptoms such as hot flushes and night sweats, remod-
elling of body shape, shifting social roles (for example,
children moving away from home), and onset of chronic
illnesses (such as diabetes and hypertension). All these
factors may interact to facilitate the development of de-
pressive symptoms during the MT. As depression and
poor lifestyle practices in mid life have been associated
with poor health outcomes in older age [11,27-29], de-
veloping health promotion interventions that are rele-
vant to women in the MT seem not only desirable, but a
necessity.
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In summary, published observational data suggest that
women undergoing the MT are at increased risk of clinic-
ally significant depressive symptoms and highlight numer-
ous health and behavioural factors that might potentially
mediate such increased risk. We have designed a health
promotion intervention that seeks to address these risk
factors systematically and to enhance behaviours associ-
ated with good mental health outcomes. More specifically,
this study will aim to address the following:
1. determine the efficacy of a telephone-medicated
health promotion intervention, compared with usual
care, in decreasing the 12-month incidence of
clinically significant symptoms of depression in
women undergoing the menopausal transition who
do not have clinically significant symptoms of
depression or mental disorders at the time of entry
into the study,
2. determine the efficacy of a telephone-mediated
health promotion intervention in decreasing the
12-month incidence of major depressive episodes in
women undergoing the menopausal transition,
compared to usual care,
3. measure the effect of a telephone-mediated health
promotion intervention in decreasing the severity of
depressive symptoms over 12 months compared to
usual care,
4. ascertain the prevalence of clinically significant
symptoms of depression among community-dwelling
Western Australian women undergoing the
menopausal transition.
Methods/Design
Trial design
The Healthy Transition Trial (HTT) is a randomised,
parallel, controlled trial of a telephone-driven health pro-
motion intervention designed to prevent the onset of clin-
ically significant symptoms of depression during the MT.
The allocation ratio will be 1:1.
Participants
We will use the Australian Electoral Commission roll to
obtain a random extraction of 40,000 women aged 45 to
55 years living in the Perth metropolitan area (enrolment
to vote is mandatory for all adults in Australia). They
will be contacted by post to confirm their perimeno-
pausal status (menopausal transition) and to assess the
prevalence of clinically significant symptoms of depres-
sion (Patient Health Questionnaire, PHQ-9 score ≥15).
They will be asked to return their screening question-
naire alongside the signed consent form, and those with
PHQ-9 < 15 will be invited to join the trial. This screen-
ing questionnaire will take approximately 30 minutes to
complete and will collect the following information:
1. demographics including date and place of birth, age,
marital status, number of children, educational
attainment, living arrangements;
2. regularity of menstrual cycles to establish
menopausal status;
3. history of life-limiting medical illnesses;
4. presence of significant hearing or visual impairment;
5. current and past common medical conditions,
including depressive and anxiety disorders;
6. alcohol use, as measured by the Alcohol Use
Disorders Identification Test (AUDIT, details below);
7. history of gynaecological surgery and medical
procedures (for example, contraceptive implants)
that may affect the assignment of menopausal
status;
8. prescription and non-prescription medications
(including hormone therapy);
9. depressive and anxiety symptoms, as rated by the
Hospital Anxiety and Depression Scale (HADS,
details below);
10. past history of schizophrenia, schizoaffective,
delusional or bipolar disorder; and
11. general practitioner’s (GP) details and permission
for the study team to liaise with GP.
For the trial, we will include women who are:
1. aged 45 to 55 years;
2. experiencing no, or sub-threshold depressive
symptoms (PHQ-9 < 15);
3. experiencing recent (last 5 years) onset of irregular
menstrual cycles (≥7 days difference in length of
consecutive cycles) OR ≥2 skipped cycles and at
least one interval of amenorrhea of 60 or more
days; and
4. amenorrhoeic for <12 months.
Volunteers will be excluded from participating for the
following reasons:
1. they disclose a history of gynaecological surgery
that compromises the ability to assign menopausal
status (that is, hysterectomy, bilateral
oophorectomy, or endometrial ablation);
2. they report an illness that may impact upon
12-month survival (for example, metastatic cancer);
3. they receive medical treatment or undergo medical
procedures that hinder ability to assign menopausal
status (hormone therapy, hormonal intrauterine
devices, contraceptive implants, patches or
medications);
4. there is evidence of clinically significant depressive
symptoms (PHQ 9 ≥ 15) or major depressive
episode at the time of assessment;
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5. there is evidence of concurrent alcohol abuse or
dependency (AUDIT ≥15);
6. they report past or current history of schizophrenia,
delusional, schizoaffective or bipolar disorder;
7. there is evidence of significant hearing
impairment that may compromise telephone
communication;
8. they are not fluent in written or spoken English;
9. they plan to leave Western Australia within the
following 12 months;
10. they report active suicidal ideation;
11. they do not have an active GP or do not consent to
the research team liaising with their GP throughout
the course of the study; or
12. they fail to provide written informed consent.
Ethics
The Research Ethics and Biosafety Office of University
of Western Australia approved the research protocol and
procedures of the study (RA/4/1/4790). This trial complies
with the principles of the Declaration of Helsinki and all
participants will be required to provide written informed
consent.
Intervention
The intervention will consist of eight 30- to 45-minute
telephone sessions delivered by a qualified clinical psy-
chologist trained to work in health promotion. These
sessions will aim to accomplish the following:
1. promote a positive approach to the menopausal
transition through the provision of quality
information and building of skills and capacity to
manage identified issues;
2. offer verbal and written access to evidence-based
information about the MT and its management
and, where relevant, depression, anxiety, and
about the association between depression
and other health issues, such as diabetes,
hypertension, lipid abnormalities, and other
cardiovascular factors;
3. promote changes in hazardous lifestyle practices
associated with increased risk of depression
and associated with poor health outcomes
(physical inactivity, tobacco smoking, excessive
alcohol consumption, and poor nutrition);
4. optimise the management of chronic medical
conditions and of depressive symptoms;
5. empower participants by offering access to
relevant educational material/health resources
and by helping them improve problem-solving
techniques and rescheduling of activities; and
6. promote symptom monitoring and active
surveillance of depressive symptoms.
We will post written educational material about the
MT, depression and healthy lifestyle practices to inter-
vention participants before their first session. Sessions
will take place within 2 weeks of the baseline assessment
and again after 2, 4, 8, 12 and 26 weeks [30]. The health
promotion officer will use motivational interviewing and
problem-solving techniques to address issues that are
identified as relevant by the participant (for example, hot
flushes or physical inactivity). The intervention will be
tailored to the individual needs of each participant, based
on the stages of change model and ‘patient-centred’ ap-
proach to care [31]. It will also allow for two extra sessions
(total equal eight) to be booked if the health promotion
officer and the participant identify issues that were not
addressed to their satisfaction during the six structured
sessions. If no risks or concerns are identified, the inter-
vention will emphasise education. The structure of the
sessions described below will be individualised and the
content will be delivered according to needs. For example,
if significant anxiety or depression is identified these will
be dealt with in earlier sessions. The sessions will cover
the following areas:
1. During the first session participants will be
encouraged to describe their views/experiences of
the MT, concerns or troublesome experiences (for
example, hot flushes/night sweats, sleep disturbance,
loss of social role, prevalent morbidities, change in
body composition, symptoms of anxiety/depression,
etcetera). The Health Coach (HC) will provide
information about the physiology of the MT and, if
relevant, anxiety and depression. HC will describe
common experiences during MT and strategies used
to manage undesirable/unpleasant signs/symptoms.
Finally, participants, with the support of the HC,
will be encouraged to prepare a hierarchical list of
troublesome experiences and discuss ways to modify
them (for example, lifestyle changes, relaxation
techniques). HC and participant will then agree on
homework activities. If no major issues are identified,
the focus will be on education about the MT;
2. The second session will start with review of
homework and feedback. HC will then explain the
principles of problem solving using examples from
session 1 and from feedback, if available. The
participants will be encouraged to prepare list of
problems they are currently facing that can and
cannot be changed, and will then be asked to select
most relevant problem that can be changed, list all
possible solutions, and choose the most appropriate
one. The session will be completed with the HC
encouraging participants to prepare diary of
problems and strategies used to mitigate them
during the following week.
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3. Session three will start with a review of homework
and discussion of what did and did not work, as well
as ways to get around barriers. HC will then
highlight key aspects of a healthy lifestyle, with
particular emphasis on physical activity, nutrition,
tobacco smoking and use of alcohol. Participants will
be encouraged to review how their current lifestyle
practices conform to existing guidelines, and then
highlight practices that they would like to change.
The HC will ask them to prepare hierarchical list of
possible changes and strategies to be used, and to
consider obstacles, facilitators and outcomes using
problem solving techniques.
4. Session four will start with a review of homework
and discussion of what did and did not work, as well
as ways to get around barriers using problem
solving. Participants will then be asked to review
their current health problems, how those should be
managed and how they are being managed in
practice. Difficulties complying with medical advice
will be listed, as will be strategies that could
optimise health care. The latter will follow the
principles of problem solving. Participants will be
encouraged to prepare a list of how their health and
well-being may be optimised, as well as strategies
that could be used to achieve and sustain those
changes.
5. Session five will start with a review of homework
and discussion of what did and did not work, as well
as ways to get around barriers using problem
solving. Participants will then be encouraged to
describe their understanding of what depression is,
as well as its key symptoms and treatment options.
The HC will then discuss with participants how to
identify the onset of clinically significant depressive
symptoms and strategies to respond to their
presence appropriately (where/how/why to seek
help, who to contact). During the subsequent week,
participants will be encouraged to prepare and
maintain diary of MT symptoms, lifestyle practices
and management of current medical problems as
well as active monitoring of depression, including
obstacles, facilitators and strategies to overcome
them.
6. During the sixth session, the HC will review
homework activities and will encourage discussion
of what did/not work and ways of getting around
obstacles using problem solving. The HC will
subsequently provide information about the
association between lifestyle practices, MT
symptoms, chronic medical diseases and depression,
and will review strategies to optimise good MT and
minimise the risk of depression. The session will be
concluded with a summary of key-points covered
during the previous sessions and organisation of
up to two additional sessions to address lingering
problems or concerns.
Participants who are assigned to usual care (control
group) will not have access to the health promotion offi-
cer but will take part in the collection of endpoints in
the same way as women allocated to the intervention.
As for women in the intervention group, clinically sig-
nificant findings will be communicated to treating GPs.
Outcomes and study measures
The onset of clinically significant symptoms of depres-
sion or of a major depressive episode over 12 months
represents the primary endpoint of interest of this trial.
We will use the Patient Health Questionnaire (PHQ-9)
to establish the presence of clinically significant symp-
toms of depression. The PHQ-9 is the self-administered
depression module of the PRIME-MD diagnostic instru-
ment for common mental disorders. It consists of nine
questions about how often the respondent has been bo-
thered by depressive symptoms during the past two
weeks, and each item can be scored 0 (not at all), 1
(several days), 2 (a week or more) or 3 (nearly every
day). The nine items are as follow: (a) decreased interest
or pleasure, (b) low mood, (c) sleep disturbance, (d) lack
of energy, (e) disturbed appetite, (f ) feelings of failure
or guilt, (g) poor concentration, (h) psychomotor dis-
turbance, and (i) suicidal thoughts. The scale has well-
established psychometric properties and face-validity, with
scores of 15 or greater indicating the presence of clinically
significant symptoms of depression that warrant treatment
[32]. Endpoints will be collected at 8, 26 and 52 weeks.
Another primary endpoint of interest is the onset of a
DSM-IV-TR major depressive episode during follow-up,
as ascertained by the Mini-Neuropsychiatric Interview
(MINI) 8, 26 and 52 weeks after the baseline assessment
[33]. The MINI can take between 15 and 45 minutes to
complete and it will allow us to investigate the presence of
depressive episodes that may have occurred between as-
sessments [34]. Only women who score 15 or more on the
PHQ-9 will undergo assessment with the MINI.
Secondary outcomes of interest of this trial include
changes in the severity of depressive and anxiety symp-
toms as measured by the Hospital Anxiety and Depression
Scale (HADS) [35], health-related quality of life as mea-
sured by the 12-item Short-Form Health Survey (SF-12)
[36], severity of menopausal symptoms as measured by
the Menopause Rating Scale (MRS) [37], changes in life-
style as measured by the amount and frequency of alcohol
consumed during a typical week, time spent in vigorous
and non-vigorous physical activities during a typical week,
the Food Frequency Questionnaire [29,38], weight and
height, and use of psychotropic medications. We will also
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ask participants to disclose the following sociodemo-
graphic and clinical data: age, place of birth, education at-
tainment, marital status, number of children and medical
history, including information about past diagnosis or
treatment for hypertension, diabetes, arthritis, asthma or
other chronic respiratory diseases, coronary heart disease,
stroke, neurodegenerative diseases (such as Parkinson’s
disease), depression and anxiety disorders. Table 1 sum-
marises the assessment schedule of the trial.
Sample size
Data from the Australian National Survey suggest that
the prevalence of clinically significant depression is 14%
around the MT and about 6% immediately before the
MT or after the menopause [5]. An effective intervention
should decrease the prevalence of depression amongst
these women from 14% to 6%, which would represent an
absolute risk reduction of 8%. The expected number of
women that we will need to treat to prevent one person
developing depression is 13. A sample size of 300 women
(1:1 allocation) will give the study 80% power to declare
such a difference as statistically significant (alpha = 5%).
These numbers take into account a loss of 40 women dur-
ing the course of the study.
Randomisation and blinding
People with sub-syndromal symptoms of depression are at
greater risk of developing a full-blown depressive episode
during the subsequent year than those free of such symp-
toms [39]. In order to minimise the risk of imbalance,
we will stratify the randomisation procedure of women
deemed eligible to join the study according to the pres-
ence or absence of subsyndromal symptoms of depression,
which will be defined by PHQ-9 scores between 5 and 14,
inclusive. Participants in each of these two strata will be
randomly assigned to the intervention or usual care ac-
cording to a list of random numbers generated by com-
puter in blocks of 12 or 24. As a consequence of the
design of this study, participants and the Health Promo-
tion Officer will not be blind to group allocation, but staff
responsible for the administration and coding of the MINI
will be blind to it. Both participants and staff will be
instructed not to discuss any aspects of the intervention
during assessment with the MINI. We are also mindful of
the fact that history of past depression is a risk factor for
the development of subsequent depressive episodes. Be-
cause of the randomisation, history of past depression
should not bias the results of the trial. Nonetheless, we
will monitor the study for possible imbalances and will ad-
just the analyses of outcomes, if necessary.
Statistical methods
Data analysis will be blind to group assignment. We will
use descriptive statistics to summarise study measures
and will compare their distribution at the baseline as-
sessment for the intervention and control groups using
Table 1 List and timeline of assessments for the Healthy Transition Trial (HTT)
Screening Baseline 2 months 6 months 12 months
Sociodemographic information YES - - - -
Patient Health Questionnaire (PHQ-9) YES YES YES YES YES
Five-year menstrual history YES YES YES YES YES
Gynaecological history YES YES YES YES YES
Past history of severe mental disorder YES - - - -
Severe medical illness (for example, metastatic cancer) YES - - - -
Medical morbidities checklist YES YES YES YES YES
Alcohol Use Disorders Identification Test YES YES YES YES YES
Self-reported hearing or visual impairment YES - - - -
Self-reported English fluency YES - - - -
Contact details for general practitioner YES - - - -
Hospital Anxiety and Depression Scale (HADS) - YES YES YES YES
Mini-Neuropsychiatric Interview - YES YES YES YES
Short-Form Health Survey, SF-12 - YES YES YES YES
Menopause Rating Scale (MRS) - YES YES YES YES
Food Frequency Questionnaire - YES YES YES YES
Prescription and non-prescription medications - YES YES YES YES
Self-reported weight (Kg) and height (cm) - YES YES YES YES
Smoking, alcohol and physical activity - YES YES YES YES
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t-tests, Mann-Whitney tests and Pearson’s chi-square
statistic. Analyses of outcomes will be intention-to-treat
(ITT) and will be ascertained using xtlogit models for
binary outcomes (for example, developed a depressive
episode during follow up: yes/no. Effect expressed as odds
ratio and respective 95% confidence limits) and multilevel
mixed-effects linear regression (xtmixed models) to ana-
lyse changes in scale scores over time (for example, chan-
ges in HADS scores - effect estimate expressed as mean
change of score from baseline). We will also use con-
tingency tables to calculate the number needed to treat
(NNT) for one person to benefit from the intervention,
taking into account the number of participants who may
be lost during follow up. The NNT is the reverse of the
absolute risk reduction. Alpha will be set at 5% and all
statistical tests will be two-tailed. Data from this trial will
determine if the intervention causes benefit, harm or
neither.
Discussion
Our strategy to recruit participants using the electoral
roll aims to increase the external validity of the results
of this study and offers the additional flexibility of in-
creasing the number of people approached, if necessary.
We have an established record of success for recruiting
participants into large community-based trials and of
collaborative work with primary care physicians, such
as the Health In Men Study [40] and the Depression
and Early Prevention of Suicide in General Practice
(DEPS-GP) project [26]. We are therefore confident that
our recruitment strategy will yield the required number of
participants.
We have also designed an intervention that takes into
account the reality of health care delivery in Australia,
so that the study activities can later be incorporated into
normal clinical practice through existing Medicare Bene-
fits Schedule. Sustainability requires evidence of efficacy
and of cost-effectiveness to lead to a commitment to
long-term implementation. This study aims to establish
evidence of efficacy. Furthermore, we broadly estimate
that the total cost of the intervention per participant will
be about A$412: $50 x 8 for health coaching + $2 × 6 for
correspondence. We anticipate that 13 women will need
to be treated for one to benefit, which would result in a
total cost of about A$5,500 to avoid one case of depres-
sion. The estimated annual cost of depression per patient
in Australia is approximately A$17,000 (considering an
extremely conservative 30% increase in costs since the
publication of Australian estimates in 2003) [41]. This
would result in a minimum net gain of $11,500 per year
for every 13 women treated (savings in other health areas
have not been taken into account, so savings could be
even greater). These preliminary calculations indicate that
the intervention will be cost-effective if the expected bene-
fits are confirmed.
Current evidence shows that depressive symptoms and
disorders are leading causes of disability worldwide that
are relatively common during the MT [42]. Targeting
at risk populations with preventive strategies is a cost-
effective approach to avoid further morbidity and mortal-
ity [43]. No previous studies have targeted prevention in
women at risk during the MT. This study is innovative in
proposing the use of a sound multifaceted health promo-
tion strategy to prevent depression during the MT. The
intervention will seek to empower women in their deci-
sions about beneficial changes in their lives. Our approach
is patient-centred and aims to synergistically enhance the
benefits of treatments that participants require, so that
fewer women undergoing the MT will experience clinic-
ally significant symptoms of depression (minimisation of
risk). Positive findings from this trial will provide the re-
quired evidence-base for setting up future simple and
cost-effective interventions to assist women move success-
fully through the MT.
Trial status
The HTT is currently recruiting participants.
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